Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 116496-76-5
2. N-(2-ethoxy-4-nitrophenyl)acetamide
3. Acetamide,n-(2-ethoxy-4-nitrophenyl)-
4. 2'-ethoxy-4'-nitroacetanilide
5. Cds1_004703
6. Cbmicro_030367
7. Oprea1_342150
8. Divk1c_005743
9. Schembl2204761
10. Dtxsid60387001
11. Zinc5061120
12. Mfcd00994990
13. Akos001044796
14. Ab07920
15. Ps-6223
16. Bim-0030123.p001
17. Db-049909
18. Ft-0715219
19. Sr-01000223946
20. Sr-01000223946-1
21. 4-(4-ethoxycarbonylthiazol-2-yl)piperazine-1-carboxylic Acid Tert-butyl Ester
| Molecular Weight | 224.21 g/mol |
|---|---|
| Molecular Formula | C10H12N2O4 |
| XLogP3 | 1.5 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 3 |
| Exact Mass | 224.07970687 g/mol |
| Monoisotopic Mass | 224.07970687 g/mol |
| Topological Polar Surface Area | 84.2 Ų |
| Heavy Atom Count | 16 |
| Formal Charge | 0 |
| Complexity | 264 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
NDC API
NDC Package Code : 68225-243
Start Marketing Date : 2024-03-26
End Marketing Date : 2025-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION (45mg/mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 68225-244
Start Marketing Date : 2024-03-26
End Marketing Date : 2025-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION (60mg/mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
Winrevair (sotatercept) is the first activin signaling inhibitor therapy, which is approved for the treatment of adults with pulmonary arterial hypertension.
Lead Product(s): Sotatercept
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Winrevair
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2024
Lead Product(s) : Sotatercept
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Merck's WINREVAIR™ Approved by European Commission for Pulmonary Hypertension
Details : Winrevair (sotatercept) is the first activin signaling inhibitor therapy, which is approved for the treatment of adults with pulmonary arterial hypertension.
Brand Name : Winrevair
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 26, 2024
Details:
Winrevair (sotatercept-csrk) is the first activin signaling inhibitor therapy, which is approved for the treatment of adults with pulmonary arterial hypertension.
Lead Product(s): Sotatercept
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Winrevair
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2024
Lead Product(s) : Sotatercept
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Merck Receives Positive EU CHMP Opinion for WINREVAIR™ (sotatercept) in Pulmonary Arterial Hyper...
Details : Winrevair (sotatercept-csrk) is the first activin signaling inhibitor therapy, which is approved for the treatment of adults with pulmonary arterial hypertension.
Brand Name : Winrevair
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 28, 2024
Details:
Winrevair (sotatercept-csrk) is the first activin signaling inhibitor therapy, which is approved for the treatment of adults with pulmonary arterial hypertension.
Lead Product(s): Sotatercept
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Winrevair
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Lead Product(s) : Sotatercept
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with...
Details : Winrevair (sotatercept-csrk) is the first activin signaling inhibitor therapy, which is approved for the treatment of adults with pulmonary arterial hypertension.
Brand Name : Winrevair
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 26, 2024
Details:
MK-7962 (sotatercept) is a potential first-in-class activin signaling inhibitor biologic being studied for the treatment of adult patients with pulmonary arterial hypertension.
Lead Product(s): Sotatercept
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: MK-7962
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Lead Product(s) : Sotatercept
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MK-7962 (sotatercept) is a potential first-in-class activin signaling inhibitor biologic being studied for the treatment of adult patients with pulmonary arterial hypertension.
Brand Name : MK-7962
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 28, 2023
Details:
MK-7962 (sotatercept), is an activin receptor type IIA fusion protein that acts as a ligand trap for members in the transforming growth factor-beta protein superfamily involved in remodeling and regeneration of a variety of different tissues like vasculature and fibrosis.
Lead Product(s): Sotatercept
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: MK-7962
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2023
Lead Product(s) : Sotatercept
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Merck’s Investigational Activin Signaling Inhibitor Sotatercept Improved Six-Minute Walk Distanc...
Details : MK-7962 (sotatercept), is an activin receptor type IIA fusion protein that acts as a ligand trap for members in the transforming growth factor-beta protein superfamily involved in remodeling and regeneration of a variety of different tissues like vascula...
Brand Name : MK-7962
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 06, 2023
Details:
Sotatercept,is an investigational, potential first-in-class activin receptor type IIA-Fc fusion protein demonstrated significant improvement in exercise capacity and key secondary outcome measures compared to placebo when added to background therapy.
Lead Product(s): Sotatercept
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: MK-7962
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2022
Lead Product(s) : Sotatercept
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Sotatercept,is an investigational, potential first-in-class activin receptor type IIA-Fc fusion protein demonstrated significant improvement in exercise capacity and key secondary outcome measures compared to placebo when added to background therapy.
Brand Name : MK-7962
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 10, 2022
Details:
Through the successful completion of the acquisition of Acceleron Pharma, Merck would be growing its cardiovascular portfolio and pipeline, including Acceleron’s lead therapeutic candidate, sotatercept, has a novel mechanism of action with the potential to improve short-term.
Lead Product(s): Sotatercept
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: ACE-011
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Merck
Deal Size: $11,500.0 million Upfront Cash: $11,500.0 million
Deal Type: Acquisition November 19, 2021
Lead Product(s) : Sotatercept
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Merck
Deal Size : $11,500.0 million
Deal Type : Acquisition
Merck Completes Acquisition of Acceleron Pharma Inc.
Details : Through the successful completion of the acquisition of Acceleron Pharma, Merck would be growing its cardiovascular portfolio and pipeline, including Acceleron’s lead therapeutic candidate, sotatercept, has a novel mechanism of action with the potentia...
Brand Name : ACE-011
Molecule Type : Large molecule
Upfront Cash : $11,500.0 million
November 19, 2021
Details:
Under the terms of the acquisition agreement, Merck will acquire all outstanding shares of Acceleron including its pipeline having lead therapeutic candidate, sotatercept, in Phase 3 trials as add-on to current standard of care for the treatment of PAH.
Lead Product(s): Sotatercept
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: ACE-011
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Merck & Co
Deal Size: $11,500.0 million Upfront Cash: $11,500.0 million
Deal Type: Acquisition September 30, 2021
Lead Product(s) : Sotatercept
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : $11,500.0 million
Deal Type : Acquisition
Merck to Acquire Acceleron Pharma Inc
Details : Under the terms of the acquisition agreement, Merck will acquire all outstanding shares of Acceleron including its pipeline having lead therapeutic candidate, sotatercept, in Phase 3 trials as add-on to current standard of care for the treatment of PAH.
Brand Name : ACE-011
Molecule Type : Large molecule
Upfront Cash : $11,500.0 million
September 30, 2021
Details:
The SPECTRA Phase 2 trial is a single arm, open-label, multi-center exploratory study to determine the eects of sotatercept plus standard of care in adults with WHO functional class III PAH.
Lead Product(s): Sotatercept
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: ACE-011
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2021
Lead Product(s) : Sotatercept
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The SPECTRA Phase 2 trial is a single arm, open-label, multi-center exploratory study to determine the eects of sotatercept plus standard of care in adults with WHO functional class III PAH.
Brand Name : ACE-011
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 19, 2021
Details:
A total of 106 patients were randomized in a 3:3:4 ratio to receive placebo, sotatercept 0.3 mg/kg, or sotatercept 0.7 mg/kg subcutaneously every three weeks on top of standard-of-care therapies.
Lead Product(s): Sotatercept
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: ACE-011
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2021
Lead Product(s) : Sotatercept
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : A total of 106 patients were randomized in a 3:3:4 ratio to receive placebo, sotatercept 0.3 mg/kg, or sotatercept 0.7 mg/kg subcutaneously every three weeks on top of standard-of-care therapies.
Brand Name : ACE-011
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 19, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
Market Place
